Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of colistimethate sodium for injection in adult hospital-acquired pneumonia
CTR20252108Phase 3Active
- Sponsor
- Aosaikang Biotherapeutics
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of colistimethate sodium in hospital-acquired pneumonia (HAP), sponsored by Aosaikang Biotherapeutics. Started Jul 2025; status: active.
02
Drugs
colistimethate sodium
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on CTR20252108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252108.